Search

Your search keyword '"Kaur, Ripandeep"' showing total 23 results
Start Over Author "Kaur, Ripandeep" Publication Year Range Last 50 years
23 results on '"Kaur, Ripandeep"'

10. List of Contributors

Author

Abdelghany, Sara, primary, Amjad, Muhammad W., additional, Anwar, Firoz, additional, Athawale, R., additional, Augustine, Rimesh, additional, Beg, Sarwar, additional, Butt, Adeel M., additional, Chaudhary, Sonam, additional, Chougule, Mahavir B., additional, Derakhshan, Mohammad A., additional, Gajbhiye, Virendra, additional, Giri, Namita, additional, Gothwal, Avinash, additional, Greish, Khaled, additional, Gupta, Vivek, additional, Gupta, Umesh, additional, Gurnany, Ekta, additional, Jain, Atul, additional, Jain, Ashay, additional, Jasim, Anfal, additional, John, Johnson V., additional, Kaur, Ripandeep, additional, Kesharwani, Prashant, additional, Khan, Iliyas, additional, Khurana, Rajneet K., additional, Kiani, Vali, additional, Kim, I.L, additional, Kumar, Lalit, additional, Kumar, Rajendra, additional, Kumar, Vikas, additional, Kurup, N., additional, Lohan, Shikha, additional, Maheshwari, Rahul, additional, Mansoori, Mohammad H., additional, Mishra, Vijay, additional, Mohd Amin, Mohd C.I., additional, Rahman, Mahfoozur, additional, Rani, Sarita, additional, Rezayat, Seyed M., additional, Saini, Sumant, additional, Samad, Abdus, additional, Sharma, Ashok K., additional, Shegokar, R., additional, Singh, Bhupinder, additional, Soni, Namrata, additional, Tavakol, Behnaz, additional, Tavakol, Shima, additional, Tekade, Muktika, additional, Tekade, Rakesh K., additional, Vaidya, Bhuvaneshwar, additional, Verma, Amita, additional, Verma, Shivani, additional, and Yang, R., additional

Published
2017
Full Text
View/download PDF

12. Biocompatible phospholipid‐based nanovesicular drug delivery system of ketoprofen: Systematic development, optimization, and preclinical evaluation.

Author

Bimbrawh, Senha, Chopra, Shruti, Ansari, Mohammad Javed, Alrobaian, Majed, Almalki, Waleed H, Alharbi, Khalid S, Alenezi, Sattam K, Kaur, Ripandeep, Beg, Sarwar, and Bhatia, Amit

Subjects
DRUG delivery systems, TERPENES, LABORATORY rats, COLD storage, NONSTEROIDAL anti-inflammatory agents
Abstract

The present work involved development of phospholipid‐based permeation enhancing nanovesicles (PENVs) for topical delivery of ketoprofen. Screening of phospholipids and process parameters was performed. Central composite design was used for optimization of factors, that is, amount (%, w/w) of phospholipid and ethanol at three levels. The optimized nanovesicles (NVs) were loaded with different terpenes and then incorporated into a gel base. Optimized NVs exhibited 69% entrapment efficiency, 51% transmittance, 328 nm mean vesicle size, and polydispersity index of 0.25. In vitro release kinetics evaluation indicated best fitting as per Korsemeyer–Peppa's model and drug release via Fickian‐diffusion mechanism. The optimized NVs loaded with mint terpene showed minimal degree of deformability and maximal elasticity as compared with the conventional NVs and liposomes. Rheology and texture analysis indicated pseudoplastic flow and smooth texture of the vesicle gel formulation. Ex vivo permeation studies across Wistar rat skin indicated low penetration (0.43‐fold decrease) and high skin retention (4.26‐fold increase) of ketoprofen from the optimized PENVs gel vis‐à‐vis the conventional gel. Skin irritancy study indicated lower scores for PENVs gel construing its biocompatible nature. Stability studies confirmed cold storage is best suitable for vesicle gel, and optimized PENVs were found to be suitable for topical delivery of ketoprofen. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Improved biopharmaceutical attributes of lumefantrine using choline mimicking drug delivery system: preclinical investigation on NK-65 P.berghei murine model

Author

Kaur, Ripandeep, Gorki, Varun, Katare, OP, Dhingra, Neelima, Chauhan, Monika, Kaur, Ranjot, Nirmalan, Niroshini, and Singh, Bhupinder

Abstract

Lumefantrine (LMF) is first-line antimalarial drug, possesses activity against almost all human malarial parasites, but the in vivo activity of this molecule gets thwarted due to its low and inconsistent oral bioavailability (i.e. 4–12%) owing to poor biopharmaceutical attributes. Lumefantrine phospholipid complex (LMF-PC) was prepared by rota-evaporation method following job’s plot technique for the selection of apt stoichiometric ratios. Docking studies were carried out to determine the possible interaction(s) of LMF with phosphatidylcholine analogue. Comparative in vitro physiochemical, solid-state characterization, MTT assay, dose-response on P. falciparum, in vivo efficacy studies including pharmacokinetic and chemosuppression on NK-65 P. berghei infected mice were carried out. Aqueous solubility was distinctly improved (i.e. 345 times) with phospholipid complex of LMF. Cytotoxicity studies on Hela and fibroblast cell lines demonstrated safety of LMF-PC with selectivity indices of 4395 and 5139, respectively. IC50 value was reduced almost 2.5 folds. Significant enhancement in Cmax (3.3-folds) and AUC (2.7-folds) of rat plasma levels indicated notable pharmacokinetic superiority of LMF-PC over LMF suspension. Differential leukocytic count and cytokine assay delineated plausible immunoregulatory role of LMF-PC with nearly 98% chemosuppression and over 30 days of post-survival. Superior antimalarial efficacy and survival time with full recovery of infected mice revealed through histopathological studies.

Published
2021
Full Text
View/download PDF

18. Inhalational Drug Delivery in Pulmonary Aspergillosis

Author

Kaur, Ranjot, Kaur, Ripandeep, Singh, Charan, Kaur, Shahdeep, Goyal, Amit K, Singh, Kamalinder, Singh, Bhupinder, Kaur, Ranjot, Kaur, Ripandeep, Singh, Charan, Kaur, Shahdeep, Goyal, Amit K, Singh, Kamalinder, and Singh, Bhupinder

Abstract

Pulmonary infections have long represented one of the major threats to humans. These vary from acute to chronic conditions, depending upon the underlying disease of the airways. Pulmonary aspergillosis (PMAP) has raised vital concerns in the immunocompromised patients. The fungal infection is difficult to diagnose in the early stages, often making the disease more complicated. Currently, three classes of antifungal agents are available on the market for the treatment of pulmonary infections. These agents are available in oral and intravenous forms only, which limits the availability of therapeutic concentrations of drug in the lungs for longer durations. Consequently, this leads to therapeutic failure and/or resistance of the organism(s) towards the antifungal agents because the optimum amount of drug does not reach the infection site. To combat the issues associated with the conventional regimens, inhalation of antifungal agents is gaining importance because administration to the lungs offers huge advantages of localized and targeted delivery. A wide range of inhalational devices such as nebulizers, dry powder inhalers, and metered dose inhalers are available on the market to deliver drug molecules to the lungs effectively. However, their clinical utility is limited to conditions such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis only. For a few decades, inhalation therapy has also been gaining importance to treat infectious diseases such as tuberculosis and aspergillosis, though more research efforts are required to make the transition from bench to bedside. The current review provides an explicit account of the potential role of inhalation drug delivery in PMAP.

Published
2019

23. Intranasal delivery of polymer-anchored lipid nanoconstructs of artemether-lumefantrine in Plasmodium bergheiANKA murine model

Author

Kaur, Ripandeep, Gorki, Varun, Singh, Guneet, Kaur, Ranjot, Katare, O.P., Nirmalan, Niroshini, and Singh, Bhupinder

Abstract

Cerebral malaria is a serious plasmodial infection that calls for immediate treatment for parasitic clearance from brain. Oral regimen of cerebral malaria is an impracticable option, it being often associated with problems like impaired consciousness, nausea and anorexia. The current research studies were, accordingly, undertaken to develop a patient-friendly non-invasive and rapid therapy via intranasal delivery of artemether (AM) and lumefantrine (LMF) employing their surface-modified lipidic nanocarriers (LNCs) using N, N, N trimethyl chitosan (TMC) as the polymer. Systematically developed employing Quality-by-Design (QbD) principles, LNCs and TMC-LNCs exhibited particle size of 63.7 and 80.8 nm, polydispersity of 0.19 and 0.28, respectively, along with modulated drug release profile for a period of 48 h. TMC-LNCs indicated nearly 2- and 7-folds enhancement in the mucoadhesive strength and nasal mucosal permeation vis-à-visconventional LNCs and pure drug(s) suspension, respectively. In vitro nitric oxide assay unraveled the potential of both TMC-LNCs and LNCs to trigger macrophages for stimulating innate immune response against the parasites. Brain biodistribution studies in female C57BL/6 mice indicated higher drug concentrations in mice brain with intranasally delivered TMC-LNCs over intranasal and peroral AM-LMF suspension. Further, the speed and effectiveness of TMC-LNCs and LNCs in eradicating Plasmodium bergheiANKA strain in the murine model was also evaluated. Intranasal TMC-LNC demonstrated considerable in vivoanti-plasmodial efficacy with over 95% parasite suppression on day 7, followed by intranasal LNCs (82.5%), intranasal AM-LMF (79.1%) and peroral AM-LMF (46.3%). Overall, the surface-modified formulation, i.e.,intranasal TMC-LNCs demonstrated markedly superior efficacy and parasitic suppression in brain.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results